Raul Rabadan

Raul Rabadan

Auto-generated profile, based on publicly available information

Raul Rabadan

Program for Mathematical Genomics, Department of Systems Biology, Columbia University, New York, USA

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2016 in Cell
Verified
Journal Article
Closed access
MCMichele Ceccarelli
Michele Ceccarelli
FBFloris Barthel
Floris Barthel
TMTathiane M. Malta
Tathiane M. Malta
TSThais S. Sabedot
Thais S. Sabedot
SSSofie Reda Salama
Sofie Reda Salama
EZErik Zmuda
Erik Zmuda

1 April 2012 in Cancer Cell
Verified
Journal Article
Closed access
DDDianne H. Dapito
Dianne H. Dapito
AMAli Mencin
Ali Mencin
GGGeum-Youn Gwak
Geum-Youn Gwak
JPJean-Philippe Pradere
Jean-Philippe Pradere
MJMyoung-Kuk Jang
Myoung-Kuk Jang
RSRobert F. Schwabe
Robert F. Schwabe

16 June 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
ETEnrico Tiacci
Enrico Tiacci
VTVladimir Trifonov
Vladimir Trifonov
GSGianluca Schiavoni
Gianluca Schiavoni
AHAntony Holmes
Antony Holmes
WKWolfgang Kern
Wolfgang Kern
‪‪‪Brunangelo ‪Falini
‪Brunangelo ‪Falini
Hairy-cell leukemia (HCL) is a well-defined clinicopathological entity whose underlying genetic lesion is still obscure. We searched for HCL-associated mutations by performing massively parallel sequencing of the whole exome of leukemic and matched normal cells purified from the peripheral blood of an index patient with HCL. Findings were validated by Sanger sequencing in 47 additional patients with HCL. Whole-exome sequencing identified five missense somatic clonal mutations that were confirmed on Sanger sequencing, including a heterozygous mutation in BRAF that results in the BRAF V600E variant protein. Since BRAF V600E is oncogenic in other tumors, further analyses were focused on this genetic lesion. The same BRAF mutation was noted in all the other 47 patients with HCL who were evaluated by means of Sanger sequencing. None of the 195 patients with other peripheral B-cell lymphomas or leukemias who were evaluated carried the BRAF V600E variant, including 38 patients with splenic marginal-zone lymphomas or unclassifiable splenic lymphomas or leukemias. In immunohistologic and Western blot studies, HCL cells expressed phosphorylated MEK and ERK (the downstream targets of the BRAF kinase), indicating a constitutive activation of the RAF–MEK–ERK mitogen-activated protein kinase pathway in HCL. In vitro incubation of BRAF-mutated primary leukemic hairy cells from 5 patients with PLX-4720, a specific inhibitor of active BRAF, led to a marked decrease in phosphorylated ERK and MEK. The BRAF V600E mutation was present in all patients with HCL who were evaluated. This finding may have implications for the pathogenesis, diagnosis, and targeted therapy of HCL. (Funded by Associazione Italiana per la Ricerca sul Cancro and others.)

9 March 2011 in Nature
Verified
Journal Article
Open access
PDF file
LPLaura Pasqualucci
Laura Pasqualucci
DDDavid Dominguez-Sola
David Dominguez-Sola
ACAnnalisa Chiarenza
Annalisa Chiarenza
GFGiulia Fabbri
Giulia Fabbri
AGAdina Grunn
Adina Grunn
RDRiccardo Dalla-Favera
Riccardo Dalla-Favera
B-cell non-Hodgkin’s lymphoma comprises biologically and clinically distinct diseases the pathogenesis of which is associated with genetic lesions affecting oncogenes and tumour-suppressor genes. We report here that the two most common types—follicular lymphoma and diffuse large B-cell lymphoma—harbour frequent structural alterations inactivating CREBBP and, more rarely, EP300, two highly related histone and non-histone acetyltransferases (HATs) that act as transcriptional co-activators in multiple signalling pathways. Overall, about 39% of diffuse large B-cell lymphoma and 41% of follicular lymphoma cases display genomic deletions and/or somatic mutations that remove or inactivate the HAT coding domain of these two genes. These lesions usually affect one allele, suggesting that reduction in HAT dosage is important for lymphomagenesis. We demonstrate specific defects in acetylation-mediated inactivation of the BCL6 oncoprotein and activation of the p53 tumour suppressor. These results identify CREBBP/EP300 mutations as a major pathogenetic mechanism shared by common forms of B-cell non-Hodgkin’s lymphoma, with direct implications for the use of drugs targeting acetylation/deacetylation mechanisms.

31 July 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LPLaura Pasqualucci
Laura Pasqualucci
VTVladimir Trifonov
Vladimir Trifonov
GFGiulia Fabbri
Giulia Fabbri
JMJing Ma
Jing Ma
DRDavide Rossi
Davide Rossi
RDRiccardo Dalla-Favera
Riccardo Dalla-Favera
Laura Pasqualucci and Riccardo Dalla-Favera and colleagues report exome sequencing and copy-number analyses of diffuse large B-cell lymphomas. Their analyses identified mutations in genes not previously implicated in DLBCL pathogenesis, such as genes encoding chromatin modifiers such as MLL2. Diffuse large B-cell lymphoma (DLBCL) is the most common form of human lymphoma. Although a number of structural alterations have been associated with the pathogenesis of this malignancy, the full spectrum of genetic lesions that are present in the DLBCL genome, and therefore the identity of dysregulated cellular pathways, remains unknown. By combining next-generation sequencing and copy number analysis, we show that the DLBCL coding genome contains, on average, more than 30 clonally represented gene alterations per case. This analysis also revealed mutations in genes not previously implicated in DLBCL pathogenesis, including those regulating chromatin methylation (MLL2; 24% of samples) and immune recognition by T cells. These results provide initial data on the complexity of the DLBCL coding genome and identify novel dysregulated pathways underlying its pathogenesis.

11 February 2019 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JZJunfei Zhao
Junfei Zhao
ACAndrew X. Chen
Andrew X. Chen
RGRobyn D. Gartrell
Robyn D. Gartrell
ASAndrew M. Silverman
Andrew M. Silverman
LALuis Aparicio
Luis Aparicio
RRRaul Rabadan
Raul Rabadan